Carboplatin plus Paclitaxel

Phase 3Small molecule

Bayer

Carboplatin plus Paclitaxel is one of 132 small molecule programs targeting Chemotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

131

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemotherapyNot yet recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerRecruiting

ChemotherapyPreclinical

Not yet recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lazcluze

Johnson & Johnson

Phase 3

8 2

Lynparza

AstraZeneca

Phase 3

6 3

Ensacove

XXcovery Holdings, Inc.

Phase 3

8 4

Carboplatin plus Paclitaxel

Bayer

Phase 3

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Ovarian Cancer

NCT07023484

Q3 2029

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06726265

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting·TThe University of Hong Kong·Phase 2·NCT07022535·18 enrolled

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting·TThe University of Hong Kong·Phase 2·NCT07023484·126 enrolled

Non-Small Cell Lung Cancer2 trials

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Terminated· Bayer logo

Bayer·Phase 3·NCT00300885·926 enrolled

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Active, not recruiting·IImmutep S.A.S.·Phase 3·NCT06726265·756 enrolled

Chemotherapy1 trial

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruiting·SShandong Cancer Hospital and Institute·N/A·NCT06649448·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Carboplatin plus Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin plus Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin plus Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Carboplatin plus Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Ovarian Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News